Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

This publication has 68 references indexed in Scilit:

• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  Proceedings of the National Academy of Sciences, 2007
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
  Science, 2007
• EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity
  Cancer Research, 2007
• Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
  British Journal of Cancer, 2006
• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
  Journal of Clinical Investigation, 2006
• Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
  Nature Medicine, 2006
• BRAF mutation predicts sensitivity to MEK inhibition
  Nature, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004